Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in ZNTL held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | Squadron Capital Management LLC | 4.1M | $20.0M | +2.4% | 5.796% | 6.21% |
| 2 | 5AM Venture Management, LLC | 3.9M | $19.1M | 0.0% | 5.546% | 6.65% |
| 3 | BlackRock, Inc. | 3.8M | $18.2M | +195.6% | 5.273% | 0.00% |
| 4 | TWO SIGMA INVESTMENTS, LP | 3.0M | $14.7M | +2.3% | 4.249% | 0.01% |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2.8M | $13.8M | +22.7% | 3.983% | 0.00% |
| 6 | CITADEL ADVISORS LLC | 2.3M | $11.3M | +33.1% | 3.284% | 0.00% |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 1.6M | $7.8M | -17.0% | 2.260% | 0.01% |
| 8 | Opaleye Management Inc. | 1.4M | $6.9M | 0.0% | 1.984% | 0.62% |
| 9 | ORBIMED ADVISORS LLC | 1.4M | $6.7M | — | 1.953% | 0.12% |
| 10 | Decheng Capital LLC | 1.3M | $6.4M | 0.0% | 1.859% | 0.88% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 1.3M | $6.2M | +106.8% | 1.804% | 0.00% |
| 12 | BANK OF AMERICA CORP /DE/ | 1.1M | $5.4M | -1.6% | 1.566% | 0.00% |
| 13 | Ishara Investments LP | 1.0M | $5.0M | -16.7% | 1.440% | 3.65% |
| 14 | PRIMECAP MANAGEMENT CO/CA/ | 957K | $4.6M | 0.0% | 1.345% | 0.00% |
| 15 | Soleus Capital Management, L.P. | 950K | $4.6M | — | 1.335% | 0.16% |
| 16 | STATE STREET CORP | 887K | $4.3M | +255.4% | 1.247% | 0.00% |
| 17 | VANGUARD PORTFOLIO MANAGEMENT LLC | 809K | $3.9M | +124.2% | 1.136% | 0.00% |
| 18 | PFIZER INC | 954K | $3.9M | 0.0% | 1.340% | 2.26% |
| 19 | Connor, Clark & Lunn Investment Management Ltd. | 758K | $3.7M | -4.3% | 1.065% | 0.01% |
| 20 | MILLENNIUM MANAGEMENT LLC | 664K | $3.2M | -48.5% | 0.933% | 0.00% |
| 21 | ADAR1 Capital Management, LLC | 653K | $3.2M | +351.3% | 0.917% | 0.14% |
| 22 | MARSHALL WACE, LLP | 591K | $2.9M | +50.6% | 0.831% | 0.00% |
| 23 | Qube Research & Technologies Ltd | 575K | $2.8M | -9.8% | 0.808% | 0.00% |
| 24 | D. E. Shaw & Co., Inc. | 547K | $2.7M | -63.2% | 0.768% | 0.00% |
| 25 | DIMENSIONAL FUND ADVISORS LP | 543K | $2.6M | +99.6% | 0.763% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in ZNTL — a direct measure of their conviction.
Filings activity in ZNTL during Q2 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 114 | +9.6% | 67.55% | +5.09 pp | $217M | +129% |
| Q1 2026 | 104 | +22% | 62.46% | +3.31 pp | $95M | +92% |
| Q4 2025 | 85 | 13% | 59.15% | 14.45 pp | $49M | 33% |
| Q3 2025 | 98 | 16% | 73.60% | 4.04 pp | $74M | +23% |
| Q2 2025 | 116 | 12% | 77.64% | 3.86 pp | $60M | 31% |
| Q1 2025 | 132 | 7.0% | 81.50% | 4.83 pp | $87M | 51% |
| Q4 2024 | 142 | +5.2% | 86.33% | 10.33 pp | $177M | 27% |
| Q3 2024 | 135 | — | 96.66% | — | $243M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Institutional ownership and quarterly buying activity across the largest Oncology Biotech peers.
Quick answers to the most common questions about buying ZNTL stock.
Based on Q2 2026 13F filings, institutional ownership of Zentalis Pharmaceuticals, Inc. stands at 67.5%, held across 114 reporting institutions.
Squadron Capital Management LLC is the largest reported institutional holder of ZNTL, with approximately 4,126,000 shares worth $0.02B as of Q2 2026.
Yes — 4 widely-followed marquee investors appear among the top 25 institutional holders of ZNTL, including TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC.
Our composite Smart Money Score for ZNTL is 75 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
33 institutions opened new positions in ZNTL during Q2 2026, while 19 fully exited. 69 added to existing positions and 11 trimmed.
ZNTL institutional ownership rose by 5.09 percentage points quarter-over-quarter, with a net change of +10 holders.
The top 10 institutions account for 57.5% of all reported 13F value in ZNTL, and the top 25 account for 84.6%.
Across the largest Oncology Biotech peers, institutional ownership levels are: DMRA (200.0%), FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.